- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Effectiveness of Anti-Obesity Drugs for CVD Prevention: A Clinician Discussion
For patients with obesity, prevention efforts to reduce the risk of cardiovascular disease (CVD) include both lifestyle interventions (eg, healthy diet, regular exercise) and medications, such as statins and glucagon-like peptide-1 (GLP-1) analogs. GLP-1 analogs, such as semaglutide and the dual incretin agonist tirzepatide were originally indicated for type 2 diabetes management and have recently been approved for weight loss in patients with obesity. How can these medications aid in treating CVD in patients with obesity? Anila Chadha, MD, family physician and obesity medicine physician at Dignity Health Medical Group in Bakersfield, California, discusses this topic and more in the video above.
For part 1 of our interview with Dr Chadha, please click here.
